Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

Core Viewpoint - Tevogen Bio Holdings Inc. emphasizes its significant insider ownership, with over 74% of outstanding shares held by executive officers and board members, reflecting strong leadership conviction in the company's mission and long-term strategy [2][3] Group 1: Insider Ownership - Executive officers and board members collectively hold over 74% of the company's outstanding shares, indicating a strong commitment to Tevogen's future [2] - This substantial insider ownership differentiates the company from many of its industry peers, showcasing confidence in its strategic direction [2] Group 2: Strategic Direction and Funding - The CEO, Dr. Ryan Saadi, stated that retaining majority control allows the team to make critical decisions for the company's growth and strategic philosophy [3] - Tevogen is well-funded for the next steps in developing off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers, as well as advancing its artificial intelligence initiative, Tevogen.AI [3]